Clinical trials: sponsored by Vanda Pharmaceuticals
Healthy Volunteers
Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects
The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon in the blood in smokers versus non-smokers.
- Trial name
- NCT01477619
- Testing
- Tasimelteon
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol
Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol
The purpose of this research study is to understand if there is any difference in the effects of tasimelteon when it is taken alone or in combination with alcohol.
- Trial name
- NCT01578057
- Testing
- tasimelteon, Ethanol
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Healthy Volunteers
Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
The purpose of this research study is to evaluate whether administration of a CYP1A2 inhibitor affects the single-dose pharmacokinetics of tasimelteon and its metabolites.
- Trial name
- NCT01540500
- Testing
- Tasimelteon, Fluvoxamine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen.
- Trial name
- NCT01348100
- Testing
- Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Excessive Somnolence
VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness
The purpose of this study is to determine the safety and efficacy of VSF-173 compared to placebo in treatment of induced excessive sleepiness.
- Trial name
- NCT00467441
- Testing
- VSF-173
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals